Related Experiment Videos
Aspirin in the prevention of thrombosis
1Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland.
Insights
Aspirin
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Platelet inhibition is a recognized strategy for preventing thrombus formation.
- Aspirin's mechanism of inhibiting platelet function is well-understood.
- Despite extensive research, definitive recommendations for aspirin in primary prevention of acute myocardial infarction remain elusive.
Purpose of the Study:
- To evaluate the efficacy of aspirin in primary and secondary prevention of cardiovascular events.
- To explore the role of aspirin and other antiplatelet agents in managing thrombus formation.
- To assess the current evidence regarding aspirin's benefits and risks in cardiovascular disease prophylaxis.
Main Methods:
- Review of numerous clinical studies on aspirin and antiplatelet agents.
- Analysis of data concerning primary and secondary prevention of myocardial infarction.
- Examination of studies investigating aspirin's effects on platelet function and cardiovascular outcomes.
Main Results:
- Evidence for aspirin's efficacy in primary prevention of acute myocardial infarction is inconclusive.
- A minority of studies show a beneficial effect of aspirin and other antiplatelet agents in secondary prevention.
- Studies with positive results often used high-dose aspirin, potentially involving mechanisms beyond cyclo-oxygenase inhibition.
Conclusions:
- Firm recommendations for aspirin in primary cardiovascular prevention cannot be made due to insufficient clear evidence.
- Cautious patient selection based on cardiovascular risk profile is crucial for aspirin therapy.
- Management of traditional risk factors (tobacco, obesity, hypertension, etc.) remains paramount and is proven beneficial, unlike aspirin therapy.
- Aspirin carries risks, including potentially fatal hemorrhage, necessitating thorough physician and patient understanding before prescription.
Abstract:
More than a decade has passed since the introduction of the concept that inhibition of platelet function may be helpful in preventing the initiation of thrombus formation. Aspirin has been recognized as inhibiting normal platelet function and the mechanism has been clearly delineated. Legions of patients have been studied to answer the question of whether aspirin is efficacious in the primary prevention of acute myocardial infarction. At the present time, however, a solid, clear answer is not available and firm recommendations cannot be made. A large number of studies evaluating aspirin and other antiplatelet agents in the prevention or delay of recurrent myocardial infarction (secondary prevention) have been completed and those studies reporting a favorable beneficial effect are in the minority. In these secondary prevention studies reporting success, the doses of aspirin employed were large enough to inhibit both the cyclo-oxygenase system and thromboxane A2 production as well as the synthesis of prostacyclin. Thus, in these studies if aspirin is effective in reducing adverse cardiovascular events, its efficacy is being mediated by an unknown mechanism. If the reader of the few studies that report positive results is convinced of the benefit of aspirin, it must be emphasized that thoughtful, cautious patient selection based upon the individual's cardiovascular risk profile must be exercised. Individual variation may exist with respect to aspirin's beneficial effect. It must be absolutely recognized that aspirin or any antiplatelet agent does not in any way substitute for the removal or treatment of coexisting risk factors such as tobacco, obesity, hypercholesterolemia, hyperlipidemia, hypertension, and metabolic disease. In contrast to aspirin, control of the above risk factors has been established as beneficial. Aspirin is not free of undesirable side-effects; fatalities secondary to hemorrhage have been reported, and these must be known in detail and understood by both physician and patient before this agent is prescribed in the prophylactic treatment of cardiovascular disease.